After three knockbacks by the FDA, Outlook Therapeutics has finally pushed its therapy for wet age-related macular ...

Chris McDonald has been named the next UK Minister for Science, following the resignation of Patrick Vallance last week, at ...

Netherlands- and Belgium-based biotech argenx has agreed to buy US biotech Forte Biosciences for up to $2.2 billion, ...

While a relatively minor setback for Ultomiris – which grew 14% to nearly $2.6 billion in the first half – the result is a ...

Johnson & Johnson's oral IL-23 inhibitor Icotyde, tipped to become a future blockbuster, has been recommended as a frontline ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades. Historically, therapeutic strategies primarily focused on suppressing ...

Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin mimetic, ...

The FDA has named Dexcom as the first medical device manufacturer that will take part in a pilot programme that could make it ...

Sanofi has retreated from a plan to file its anti-OX40L antibody amlitelimab for approval as a treatment for atopic ...

After a delay, Eisai and Biogen have won FDA approval for their new subcutaneous formulation of Alzheimer's disease therapy ...

Armed with new pivotal trial results, Eli Lilly plans to file for approval of its keenly anticipated new weight-loss therapy, ...

Bylvay (odevixibat) – which Ipsen acquired when it took over US biotech Albireo in a $952 million deal in 2023 – was being ...